Skip to content

Delirium Amelioration with Butyrate through Gut-Brain Health Enhancement in Colorectal Surgery (DELIGHT Trial): A Phase II, Parallel-Group, Double-Blind, Randomized Controlled Trial

Delirium Amelioration with Butyrate through Gut-Brain Health Enhancement in Colorectal Surgery (DELIGHT Trial): A Phase II, Parallel-Group, Double-Blind, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127158
Enrollment
Unknown
Registered
2026-06-25
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Surgery

Interventions

Intervention Group :Syrup with tributyrin for 14 days
Placebo Group :Syrup with placebo for 14 days

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients >=65 years old; 2. Attending Preoperative Anaesthetic Assessment Clinic (POAC) at Prince of Wales Hospital for preoperative assessments, going to have colorectal surgeries for primary colorectal carcinomas; 3. The scheduled date of surgery at least 15 days after the POAC assessment.

Exclusion criteria

Exclusion criteria: 1. Age < 65 years old 2. Unable to give informed consent 3. Colorectal surgery not performed for primary colorectal carcinoma, or additional major procedures planned in the same setting 4. Patients known to have adverse reactions to butyrate 5. Emergency operation or expected date of operation less than 15 days from assessment 6. Patients taking probiotics or butyrate supplements As long as the patients are considered competent to give their own informed consent for surgery, we will accept them to be eligible to give informed consent for this trial because mild MCI is common and often subclinical. In fact, these patients may theoretically be even more likely to derive benefits from butyrate supplementation due to its beneficial effects on neuroinflammation. To minimize confounding effect due to imbalance in MCI between treatment groups due to the small sample size of this study, the randomization will be stratified by whether the patients with and without MCI. Patient with delirium at the time of consultation will be excluded because they are considered incompetent to give informed consent.

Design outcomes

Primary

MeasureTime frame
Tolerability and adherence to preoperative oral butyrate glyceride regimen (defined as =75% of participants achieving =70% adherence, i.e., taking the study intervention for at least 10 days out of 14 days from 14 days before surgery to the day of surgery);

Secondary

MeasureTime frame
Feasibility metrics (recruitment rate, adherence rate, retention rate);Incidence of postoperative delirium (POD);Duration of postoperative delirium (POD);

Countries

China

Contacts

Public ContactCHU Hiu Man Mandy

The Chinese University of Hong Kong, Department of Acute Intensive Care

hiumanchu@cuhk.edu.hk+852 3505 1313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026